Jacobio, a China-based clinical-stage pharmaceutical company, announced on Sunday that it has received Investigational New Drug (IND) approval from the Food and Drug Administration (FDA) in the United States for the company's self-developed global first-in-class drug Aurora A inhibitor JAB-2485.
The company is planning to start a Phase I/IIa clinical trial in patients with advanced solid tumours in the United States.
The product is a highly selective small molecule Aurora A inhibitor that can inhibit Aurora A activity at the cellular level, induce apoptosis and inhibit tumour growth. The inhibitory activity of Aurora A is one thousand times higher than that of Aurora B, and has potential to benefit patients with small cell lung cancer and triple negative breast cancer.
The company's self-developed JAB-2485 is the third Aurora A inhibitor enter into clinical stage in the United States.
Perrigo's Omeprazole Magnesium Delayed-Release Mini Capsules receives US FDA final approval
Nanoscope Therapeutics names new advisors to company's Board and Management
Alcon to expand ophthalmic eye drop portfolio with acquisition of EYSUVIS
Third shot of Pfizer-BioNTech vaccine '80% effective' against Omicron in under-5s
STADA Arzneimittel's Kinpeygo receives positive EU regulator opinion for IgAN kidney disease
Astellas receives unfavourable decision in LEXISCAN(R) 0.4mg/mL US patent trial